United Therapeutics Q3 revenue rises 4%, beats estimates
UTHR•United Therapeutics' third-quarter revenue rose 4% to $832.5 million, beating the $781.22 million estimate. Net income fell 24% to $258.6 million, and diluted EPS declined 20%.
1. Quarterly results
United Therapeutics reported third-quarter revenue of $832.5 million, up 4% year over year and above the $781.22 million analyst estimate. Net income fell 24% to $258.6 million, while diluted EPS declined 20% to $5.71.
2. Sales and buyback
Higher quantities sold and a price increase contributed to growth in Tyvaso DPI and Orenitram revenue. The company said competing therapies negatively affected sales of Nebulized Tyvaso, Tyvaso DPI and Remodulin. It repurchased nearly 1 million shares in the quarter and authorized a new $2 billion buyback in October.
